Will Daman, Thiqa, GIG Gulf, Sukoon, ADNIC, and Orient cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Blincyto is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by EDE?

The EDE named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; EDE review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any UAE-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. MOHAP, DHA, DOH, or Sharjah Health Authority verifies the active license; the EDE application records both the prescribing physician and the dispensing facility.

Can I receive Blincyto at home?

The dispensing facility must be UAE-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative quote provided at intake. Delivered quote within 24h.Get my quote

Blincyto access in the UAE: the EDE named-patient pathway

How patients in the United Arab Emirates legally obtain Blincyto (blinatumomab) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in the UAE access Blincyto (blinatumomab) for B-cell precursor acute lymphoblastic leukaemia in adult and pediatric patients with minimal residual disease or in the relapsed/refractory setting under the FDA label through the EDE named-patient pathway, an Emirates Drug Establishment-administered mechanism that allows a UAE-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in AED.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Blincyto reaches patients in the UAE

Blincyto (blinatumomab, bispecific T-cell engager targeting CD19, FDA-approved 2014 across B-cell precursor ALL indications including the June 2024 expansion to consolidation in Philadelphia-chromosome-negative CD19-positive B-cell precursor ALL across treatment phases) is registered with MOHAP through Amgen UAE's affiliate for selected indications; check current status at mohap.gov.ae/en/services. Where the prescribed indication, dose, or paediatric application is not locally stocked, UAE residents access Blincyto via the Permit to Import Medicines for Personal Use, now administered by the Emirates Drug Establishment (EDE) since 29 December 2025 per mohap.gov.ae/en/mte. Hospital-led institutional imports run through the same EDE permit framework with the treating institution as importer-of-record. The legal basis is Federal Law No. 8 of 2019 on Medical Products. The Blincyto-specific clinical justification must document: CD19-positive B-cell precursor ALL with cytometry confirmation, Philadelphia-chromosome status, MRD status by flow cytometry or NGS where indication-relevant, prior treatment lines, and the FDA-label dosing schedule (continuous IV infusion via CADD pump). CRS and neurotoxicity Boxed Warning monitoring plan and the prescribing haematology team's UAE-licensure (DoH or DHA) are required. EDE permits issue typically within several working days when documentation is complete.

Where Blincyto is administered in the UAE

Blincyto requires continuous IV CADD-pump infusion in a haematology and BMT setting with CRS and neurotoxicity surveillance. UAE tertiary haematology and BMT nodes include Cleveland Clinic Abu Dhabi (CCAD) Cancer Center, BMT, and Cellular Therapies in Abu Dhabi at clevelandclinicabudhabi.ae/cancercenter, part of the M42 / Mubadala Health network; Sheikh Shakhbout Medical City (SSMC, joint venture with Mayo Clinic) Department of Oncology and Haematology in Abu Dhabi; Tawam Hospital (SEHA, affiliated with Johns Hopkins Medicine) Oncology and Paediatric Oncology in Al Ain at seha.ae; Burjeel Medical City Oncology Center of Excellence and paediatric oncology in Abu Dhabi; Al Jalila Children's Specialty Hospital Paediatric Oncology in Dubai at aljalilachildrens.ae (the DHA paediatric-tertiary node, the primary paediatric Blincyto candidate centre nationally); American Hospital Dubai Haematology and Oncology; King's College Hospital London Dubai Oncology; and Mediclinic City Hospital Oncology. CCAD and SSMC publish departmental chairs and run BMT programmes capable of Blincyto administration with the full safety-monitoring stack. Tawam handles the majority of paediatric ALL case load in the Northern Emirates and Al Ain corridor.

What Blincyto costs in the UAE

The US reference WAC for Blincyto is approximately USD 89,000 per 28-day cycle at standard adult dose per Amgen disclosures and Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Total course cost (induction plus consolidation cycles) runs USD 200,000 to USD 400,000. Amgen UAE distributes Blincyto for the registered indications; AED pricing for the registered presentations is set through MOHAP and now EDE pricing services for institutional procurement but is not consistently published as a public retail-pharmacy reference. The AED is USD-pegged at 3.6725 AED per USD. Price snapshot: 2026-05-31. Cost layers where the named-patient-import lane is invoked: cold-chain international logistics into the UAE (mid four-figure USD for refrigerated lanes via Dubai or Abu Dhabi air cargo), EDE personal-import or institutional-import permit fees (nominal), the CADD pump and 7-day continuous-infusion administration costs at the dispensing hospital, and Reserve Meds concierge fee itemised separately. For Emirati nationals at SEHA facilities (Tawam, SSMC, SKMC) on Thiqa, Blincyto procurement is institutional and OOP exposure is materially lower.

Funding and access barriers for Blincyto in the UAE

B-cell precursor ALL is the most common paediatric haematologic malignancy; the UAE handles a substantial paediatric ALL case load through Tawam, Al Jalila Children's Specialty Hospital, and CCAD paediatric. Public-sector funding: for Emirati nationals in Abu Dhabi, Thiqa-administered Daman insurance at daman.ae covers specialty haematology and oncology at SEHA facilities including named-patient imports with prior authorisation; Dubai-resident Emirati nationals receive comparable cover through Salama or ENAYA under DHA. MOHAP-administered free care for Emirati nationals applies in the Northern Emirates. Patient Affairs Department in the Office of HH Sheikh Mohamed bin Zayed and Mohammed bin Rashid Foundation grants are case-by-case for high-cost treatment. For expatriates on mandatory health insurance (Dubai's Essential Benefits Plan, Abu Dhabi's mandatory cooperative scheme), specialty haematology drug coverage including blinatumomab is policy-tier dependent; major insurers (Daman, Bupa Arabia, AXA Gulf, MetLife, Sukoon, Cigna Middle East, Allianz Worldwide Care, Mednet TPA, Nextcare TPA, NAS TPA) require prior authorisation. The cold-chain import experience is operationally well-established at Dubai and Abu Dhabi air cargo hubs. Amgen UAE compassionate-access programmes operate case-by-case.

Recent regulatory and access news for Blincyto

FDA approved (June 2024) Blincyto for consolidation in CD19-positive Philadelphia-chromosome-negative B-cell precursor ALL across treatment phases including newly diagnosed adult patients, based on ECOG-ACRIN E1910. The expanded label is at accessdata.fda.gov/scripts/cder/daf. EMA mirrors the indication expansion via the EPAR at ema.europa.eu/medicines/Blincyto. MOHAP announced on 29 December 2025 the transfer of personal-use import permit service to EDE per mohap.gov.ae/en/mte; all UAE Blincyto personal-import or institutional-import applications now route through ede.gov.ae as of 2026-05-31. MOHAP and EDE continue to revise the import guidelines for medicines via local agents at mohap.gov.ae.

Where Reserve Meds fits in Blincyto cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace EDE, and we do not replace your dispensing pharmacy. For Blincyto specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into the UAE, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Blincyto case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the EDE application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Continuous IV infusion (BiTE) administration in the UAE requires tertiary-centre inpatient and outpatient pump infrastructure; Cleveland Clinic Abu Dhabi and Tawam operate the relevant CRS and neurotoxicity monitoring protocols.

Next step

If your UAE physician has prescribed Blincyto and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Blincyto case Or message us on WhatsApp